PIKA provides an adjuvant effect to induce strong mucosal and systemic humoral immunity against SARS-CoV.
Identifieur interne : 002070 ( Main/Exploration ); précédent : 002069; suivant : 002071PIKA provides an adjuvant effect to induce strong mucosal and systemic humoral immunity against SARS-CoV.
Auteurs : Wei-Wei Gai [République populaire de Chine] ; Yan Zhang ; Di-Han Zhou ; Yao-Qing Chen ; Jing-Yi Yang ; Hui-Min YanSource :
- Virologica Sinica [ 1995-820X ] ; 2011.
Descripteurs français
- KwdFr :
- Adjuvants immunologiques (administration et posologie), Animaux, Anticorps antiviraux (immunologie), Femelle, Humains, Immunité humorale, Immunité muqueuse, Poly I-C (administration et posologie), Poly I-C (immunologie), Souris, Souris de lignée BALB C, Syndrome respiratoire aigu sévère (), Syndrome respiratoire aigu sévère (immunologie), Syndrome respiratoire aigu sévère (virologie), Vaccination, Vaccins antiviraux (administration et posologie), Vaccins antiviraux (immunologie), Vaccins inactivés (administration et posologie), Vaccins inactivés (immunologie), Virus du SRAS (immunologie).
- MESH :
- administration et posologie : Adjuvants immunologiques, Poly I-C, Vaccins antiviraux, Vaccins inactivés.
- immunologie : Anticorps antiviraux, Poly I-C, Syndrome respiratoire aigu sévère, Vaccins antiviraux, Vaccins inactivés, Virus du SRAS.
- virologie : Syndrome respiratoire aigu sévère.
- Animaux, Femelle, Humains, Immunité humorale, Immunité muqueuse, Souris, Souris de lignée BALB C, Syndrome respiratoire aigu sévère, Vaccination.
English descriptors
- KwdEn :
- Adjuvants, Immunologic (administration & dosage), Animals, Antibodies, Viral (immunology), Female, Humans, Immunity, Humoral, Immunity, Mucosal, Mice, Mice, Inbred BALB C, Poly I-C (administration & dosage), Poly I-C (immunology), SARS Virus (immunology), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (prevention & control), Severe Acute Respiratory Syndrome (virology), Vaccination, Vaccines, Inactivated (administration & dosage), Vaccines, Inactivated (immunology), Viral Vaccines (administration & dosage), Viral Vaccines (immunology).
- MESH :
- chemical , administration & dosage : Adjuvants, Immunologic, Poly I-C, Vaccines, Inactivated, Viral Vaccines.
- chemical , immunology : Antibodies, Viral, Poly I-C, Vaccines, Inactivated, Viral Vaccines.
- immunology : SARS Virus, Severe Acute Respiratory Syndrome.
- prevention & control : Severe Acute Respiratory Syndrome.
- virology : Severe Acute Respiratory Syndrome.
- Animals, Female, Humans, Immunity, Humoral, Immunity, Mucosal, Mice, Mice, Inbred BALB C, Vaccination.
Abstract
Severe Acute Respiratory Syndrome (SARS) is a deadly infectious disease caused by SARS Coronavirus (SARS-CoV). Inactivated SARS-CoV has been explored as a vaccine against SARS-CoV. However, safe and potent adjuvants, especially with more efficient and economical needle-free vaccination are always needed more urgently in a pandemic. The development of a safe and effective mucosal adjuvant and vaccine for prevention of emergent infectious diseases such as SARS will be an important advancement. PIKA, a stabilized derivative of Poly (I:C), was previously reported to be safe and potent as adjuvant in mouse models. In the present study, we demonstrated that the intraperitoneal and intranasal co-administration of inactivated SARS-CoV vaccine together with this improved Poly (I:C) derivative induced strong anti-SARS-CoV mucosal and systemic humoral immune responses with neutralizing activity against pseudotyped virus. Although intraperitoneal immunization of inactivated SARS-CoV vaccine alone could induce a certain level of neutralizing activity in serum as well as in mucosal sites, co-administration of inactivated SARS-CoV vaccine with PIKA as adjuvant could induce a much higher neutralizing activity. When intranasal immunization was used, PIKA was obligatorily for inducing neutralizing activity in serum as well as in mucosal sites and was correlated with both mucosal IgA and mucosal IgG response. Overall, PIKA could be a good mucosal adjuvant candidate for inactivated SARS-CoV vaccine for use in possible future pandemic.
DOI: 10.1007/s12250-011-3183-z
PubMed: 21468931
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001527
- to stream PubMed, to step Curation: 001527
- to stream PubMed, to step Checkpoint: 001457
- to stream Ncbi, to step Merge: 002323
- to stream Ncbi, to step Curation: 002323
- to stream Ncbi, to step Checkpoint: 002323
- to stream Main, to step Merge: 002095
- to stream Main, to step Curation: 002070
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">PIKA provides an adjuvant effect to induce strong mucosal and systemic humoral immunity against SARS-CoV.</title><author><name sortKey="Gai, Wei Wei" sort="Gai, Wei Wei" uniqKey="Gai W" first="Wei-Wei" last="Gai">Wei-Wei Gai</name><affiliation wicri:level="1"><nlm:affiliation>Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430072, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430072</wicri:regionArea><placeName><settlement type="city">Wuhan</settlement><region type="région">Hubei</region></placeName></affiliation></author><author><name sortKey="Zhang, Yan" sort="Zhang, Yan" uniqKey="Zhang Y" first="Yan" last="Zhang">Yan Zhang</name></author><author><name sortKey="Zhou, Di Han" sort="Zhou, Di Han" uniqKey="Zhou D" first="Di-Han" last="Zhou">Di-Han Zhou</name></author><author><name sortKey="Chen, Yao Qing" sort="Chen, Yao Qing" uniqKey="Chen Y" first="Yao-Qing" last="Chen">Yao-Qing Chen</name></author><author><name sortKey="Yang, Jing Yi" sort="Yang, Jing Yi" uniqKey="Yang J" first="Jing-Yi" last="Yang">Jing-Yi Yang</name></author><author><name sortKey="Yan, Hui Min" sort="Yan, Hui Min" uniqKey="Yan H" first="Hui-Min" last="Yan">Hui-Min Yan</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:21468931</idno><idno type="pmid">21468931</idno><idno type="doi">10.1007/s12250-011-3183-z</idno><idno type="wicri:Area/PubMed/Corpus">001527</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001527</idno><idno type="wicri:Area/PubMed/Curation">001527</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001527</idno><idno type="wicri:Area/PubMed/Checkpoint">001457</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001457</idno><idno type="wicri:Area/Ncbi/Merge">002323</idno><idno type="wicri:Area/Ncbi/Curation">002323</idno><idno type="wicri:Area/Ncbi/Checkpoint">002323</idno><idno type="wicri:Area/Main/Merge">002095</idno><idno type="wicri:Area/Main/Curation">002070</idno><idno type="wicri:Area/Main/Exploration">002070</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">PIKA provides an adjuvant effect to induce strong mucosal and systemic humoral immunity against SARS-CoV.</title><author><name sortKey="Gai, Wei Wei" sort="Gai, Wei Wei" uniqKey="Gai W" first="Wei-Wei" last="Gai">Wei-Wei Gai</name><affiliation wicri:level="1"><nlm:affiliation>Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430072, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430072</wicri:regionArea><placeName><settlement type="city">Wuhan</settlement><region type="région">Hubei</region></placeName></affiliation></author><author><name sortKey="Zhang, Yan" sort="Zhang, Yan" uniqKey="Zhang Y" first="Yan" last="Zhang">Yan Zhang</name></author><author><name sortKey="Zhou, Di Han" sort="Zhou, Di Han" uniqKey="Zhou D" first="Di-Han" last="Zhou">Di-Han Zhou</name></author><author><name sortKey="Chen, Yao Qing" sort="Chen, Yao Qing" uniqKey="Chen Y" first="Yao-Qing" last="Chen">Yao-Qing Chen</name></author><author><name sortKey="Yang, Jing Yi" sort="Yang, Jing Yi" uniqKey="Yang J" first="Jing-Yi" last="Yang">Jing-Yi Yang</name></author><author><name sortKey="Yan, Hui Min" sort="Yan, Hui Min" uniqKey="Yan H" first="Hui-Min" last="Yan">Hui-Min Yan</name></author></analytic><series><title level="j">Virologica Sinica</title><idno type="eISSN">1995-820X</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic (administration & dosage)</term><term>Animals</term><term>Antibodies, Viral (immunology)</term><term>Female</term><term>Humans</term><term>Immunity, Humoral</term><term>Immunity, Mucosal</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Poly I-C (administration & dosage)</term><term>Poly I-C (immunology)</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term><term>Severe Acute Respiratory Syndrome (virology)</term><term>Vaccination</term><term>Vaccines, Inactivated (administration & dosage)</term><term>Vaccines, Inactivated (immunology)</term><term>Viral Vaccines (administration & dosage)</term><term>Viral Vaccines (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adjuvants immunologiques (administration et posologie)</term><term>Animaux</term><term>Anticorps antiviraux (immunologie)</term><term>Femelle</term><term>Humains</term><term>Immunité humorale</term><term>Immunité muqueuse</term><term>Poly I-C (administration et posologie)</term><term>Poly I-C (immunologie)</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Syndrome respiratoire aigu sévère ()</term><term>Syndrome respiratoire aigu sévère (immunologie)</term><term>Syndrome respiratoire aigu sévère (virologie)</term><term>Vaccination</term><term>Vaccins antiviraux (administration et posologie)</term><term>Vaccins antiviraux (immunologie)</term><term>Vaccins inactivés (administration et posologie)</term><term>Vaccins inactivés (immunologie)</term><term>Virus du SRAS (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Adjuvants, Immunologic</term><term>Poly I-C</term><term>Vaccines, Inactivated</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Viral</term><term>Poly I-C</term><term>Vaccines, Inactivated</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Adjuvants immunologiques</term><term>Poly I-C</term><term>Vaccins antiviraux</term><term>Vaccins inactivés</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antiviraux</term><term>Poly I-C</term><term>Syndrome respiratoire aigu sévère</term><term>Vaccins antiviraux</term><term>Vaccins inactivés</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Female</term><term>Humans</term><term>Immunity, Humoral</term><term>Immunity, Mucosal</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Vaccination</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Femelle</term><term>Humains</term><term>Immunité humorale</term><term>Immunité muqueuse</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Syndrome respiratoire aigu sévère</term><term>Vaccination</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Severe Acute Respiratory Syndrome (SARS) is a deadly infectious disease caused by SARS Coronavirus (SARS-CoV). Inactivated SARS-CoV has been explored as a vaccine against SARS-CoV. However, safe and potent adjuvants, especially with more efficient and economical needle-free vaccination are always needed more urgently in a pandemic. The development of a safe and effective mucosal adjuvant and vaccine for prevention of emergent infectious diseases such as SARS will be an important advancement. PIKA, a stabilized derivative of Poly (I:C), was previously reported to be safe and potent as adjuvant in mouse models. In the present study, we demonstrated that the intraperitoneal and intranasal co-administration of inactivated SARS-CoV vaccine together with this improved Poly (I:C) derivative induced strong anti-SARS-CoV mucosal and systemic humoral immune responses with neutralizing activity against pseudotyped virus. Although intraperitoneal immunization of inactivated SARS-CoV vaccine alone could induce a certain level of neutralizing activity in serum as well as in mucosal sites, co-administration of inactivated SARS-CoV vaccine with PIKA as adjuvant could induce a much higher neutralizing activity. When intranasal immunization was used, PIKA was obligatorily for inducing neutralizing activity in serum as well as in mucosal sites and was correlated with both mucosal IgA and mucosal IgG response. Overall, PIKA could be a good mucosal adjuvant candidate for inactivated SARS-CoV vaccine for use in possible future pandemic.</div></front></TEI><affiliations><list><country><li>République populaire de Chine</li></country><region><li>Hubei</li></region><settlement><li>Wuhan</li></settlement></list><tree><noCountry><name sortKey="Chen, Yao Qing" sort="Chen, Yao Qing" uniqKey="Chen Y" first="Yao-Qing" last="Chen">Yao-Qing Chen</name><name sortKey="Yan, Hui Min" sort="Yan, Hui Min" uniqKey="Yan H" first="Hui-Min" last="Yan">Hui-Min Yan</name><name sortKey="Yang, Jing Yi" sort="Yang, Jing Yi" uniqKey="Yang J" first="Jing-Yi" last="Yang">Jing-Yi Yang</name><name sortKey="Zhang, Yan" sort="Zhang, Yan" uniqKey="Zhang Y" first="Yan" last="Zhang">Yan Zhang</name><name sortKey="Zhou, Di Han" sort="Zhou, Di Han" uniqKey="Zhou D" first="Di-Han" last="Zhou">Di-Han Zhou</name></noCountry><country name="République populaire de Chine"><region name="Hubei"><name sortKey="Gai, Wei Wei" sort="Gai, Wei Wei" uniqKey="Gai W" first="Wei-Wei" last="Gai">Wei-Wei Gai</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002070 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002070 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:21468931
|texte= PIKA provides an adjuvant effect to induce strong mucosal and systemic humoral immunity against SARS-CoV.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:21468931" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |